BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 11477665)

  • 1. Mutation analysis of the CDKN2A promoter in Australian melanoma families.
    Pollock PM; Stark MS; Palmer JM; Walters MK; Aitken JF; Martin NG; Hayward NK
    Genes Chromosomes Cancer; 2001 Sep; 32(1):89-94. PubMed ID: 11477665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
    Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
    Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation screening of the CDKN2A promoter in melanoma families.
    Harland M; Holland EA; Ghiorzo P; Mantelli M; Bianchi-Scarrà G; Goldstein AM; Tucker MA; Ponder BA; Mann GJ; Bishop DT; Newton Bishop J
    Genes Chromosomes Cancer; 2000 May; 28(1):45-57. PubMed ID: 10738302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A mutations in multiple primary melanomas.
    Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ
    N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in CDKN2A locus as potential indicator of melanoma predisposition in relatives of non-familial melanoma cases.
    Levanat S; Situm M; Crnić I; Marasović D; Puizina-Ivić N; Pokupcić N; Musani V; Komar A; Kubat M; Furac I; Karija-Vlahović M; Krizanac S
    Croat Med J; 2003 Aug; 44(4):418-24. PubMed ID: 12950144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
    Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
    Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and predisposes to melanoma.
    Liu L; Dilworth D; Gao L; Monzon J; Summers A; Lassam N; Hogg D
    Nat Genet; 1999 Jan; 21(1):128-32. PubMed ID: 9916806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families.
    Lang J; Boxer M; MacKie RM
    Br J Dermatol; 2005 Dec; 153(6):1121-5. PubMed ID: 16307646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
    Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
    Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
    Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline splicing mutations of CDKN2A predispose to melanoma.
    Loo JC; Liu L; Hao A; Gao L; Agatep R; Shennan M; Summers A; Goldstein AM; Tucker MA; Deters C; Fusaro R; Blazer K; Weitzel J; Lassam N; Lynch H; Hogg D
    Oncogene; 2003 Sep; 22(41):6387-94. PubMed ID: 14508519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
    Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
    Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
    Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families.
    Hashemi J; Bendahl PO; Sandberg T; Platz A; Linder S; Stierner U; Olsson H; Ingvar C; Hansson J; Borg A
    Genes Chromosomes Cancer; 2001 Jun; 31(2):107-16. PubMed ID: 11319798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
    Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
    Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations.
    Rizos H; Becker TM; Holland EA; Kefford RF; Mann GJ
    Oncogene; 1997 Jul; 15(5):515-23. PubMed ID: 9247305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
    Kannengiesser C; Dalle S; Leccia MT; Avril MF; Bonadona V; Chompret A; Lasset C; Leroux D; Thomas L; Lesueur F; Lenoir G; Sarasin A; Bressac-de Paillerets B
    Genes Chromosomes Cancer; 2007 Aug; 46(8):751-60. PubMed ID: 17492760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.